The promise of tumor-infiltrating lymphocytes (TIL) therapy is expanding beyond melanoma to a wide range of solid tumors, but the path to clinical success remains complex. Variability in tumor tissue ...

Successful centralization of manufacturing at i CTC, significant operational excellence initiatives focused on Amtagvi production, and R&D optimization should further reduce costs and improve gross ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial We analyzed ...

Lymphedema Treatment Act: A Critical Step for Cancer Survivors, but Unresolved Equity Gaps Persist Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment ...

New data support integrating tumor-infiltrating lymphocyte levels with nodal status to improve risk stratification in women with triple-negative breast cancer (TNBC) and pathological complete response ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

At AACR 2026, scientists showcased advances in radiotherapeutics, antibody-drug conjugates, T cell engagers, and ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...